Weekly epidemiological recordRelevé épidémiologique hebdomadaire 29 JULY 2016, 91th YEAR / 29 JUILLET 2016, 91e ANNÉENo 30, 2016, 91, 349–364
Brief review of selected topics
The following pages provide a focus on selected areas in relation to neurology. The specialists who contributed the reviews are listed in the Project Team and Partners
Neurology Atlas (2004)
Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended fo...r public health specialists
more
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
Ending Cholera—A Global Roadmap to 2030 operationalises the new global strategy for cholera control at the country level and provides a concrete path toward a world in which cholera is no longer a threat to public health
The main objectives of the SOPs are to: (i) establish standards and timelines for response activities; and (ii) guide national governments and GPEI partners in key support functions.
This new version of the SOPs presents overall response requirements for dealing with type 1, 2 and 3 poliovirus fo...llowing monovalent type 2 oral polio vaccine (mOPV2) cessation. Version 2.4 will be valid until release of revised version 3.0 (anticipated May 2018).
more